Expectations trend
FY2028 · fiscal year ending 2028-03-19 · fmp
$0.12 → $0.10 · observed estimates
Janus Living Inc (JAN)
NYSEReal EstateReit - DiversifiedSnapshot 2026-11-04
$30.75+2.26%
Close 2026-11-05 · 1-day change
NYSEReal EstateReit - DiversifiedSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for JAN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successful public offering of 25 million Class A-1 shares | It raised capital by selling 25 million shares. | Intact | Failure to maintain capital from the 25 million share offering | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-03-19 · fmp
$0.12 → $0.10 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
JAN is a real-estate growth story tied to senior housing, with growth supported by acquisitions and higher same-store adjusted NOI. The current thesis is mildly favorable, but confidence is low and the overall thesis state is insufficient because there is too little recent financial history.
JAN carries a 1.75 premium versus peers, with the valuation model pointing to a durable premium, but confidence in that assessment is low. The evidence does not specify what operating expectations the market has already priced in, and the low fragility reading does not establish that the shares are inexpensive.
Near term, same-store adjusted NOI growth has exceeded earlier guidance, and management raised its 2026 outlook for both NOI growth and diluted EPS; diluted EPS improved from a loss in the first quarter to a small profit in the second. Acquisitions are active and broadly aligned with stated cash NOI yield goals, though that priority is rated mixed. Earnings remain a watchpoint given erratic recent surprises, and a guidance reversal would damage confidence.
Over the next one to three years, the thesis depends on sustaining NOI growth, meeting the raised guidance, and integrating acquisitions at the stated yields. Fed rate cuts could support the real-estate sector, while weakness among sector peers could remove that support. A reversal of the recent guidance increase is a key downside scenario.
The one-to-three-year view has encouraging operating momentum, but low confidence, a peer valuation premium, and limited thesis history leave the case uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company guides 2026 EPS between $0.23 and $0.27. |
| Intact |
| Diluted EPS falls below $0.23 in FY26 |
Diluted EPS: $-0.02 per share FY2026-Q3; GAAP. Published target: EPS between $0.23 and $0.27. Annual target cannot be compared with a quarterly or TTM observation. Nov 3, 2026-0.02 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Same-Store Adjusted NOI growth of 11% - 15% | Janus Living aims for 11% to 15% growth in same-store NOI. | Intact | Same-Store Adjusted NOI growth falls below 11% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “The Company continues to see compelling and accretive investment opportunities.” “Janus Living is targeting a 7.5% to 8.5% cash NOI yield upon stabilization.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$1.23B → $1.23B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-20 | $0.12 | $1,227,410,834 | 3 / 8 |
| 2026-10-21 | $0.12 | $1,227,410,834 | 3 / 8 |
| 2026-10-22 | $0.12 | $1,227,410,834 | 3 / 8 |
| 2026-10-23 | $0.12 | $1,227,410,834 | 3 / 8 |
| 2026-10-24 | $0.12 | $1,227,410,834 | 3 / 8 |
| 2026-10-25 | $0.12 | $1,227,410,834 | 3 / 8 |
| 2026-10-26 | $0.12 | $1,227,410,834 | 3 / 8 |
| 2026-10-27 | $0.12 | $1,227,410,834 | 3 / 8 |
| 2026-10-28 | $0.12 | $1,227,410,834 | 3 / 8 |
| 2026-10-29 | $0.12 | $1,227,410,834 | 3 / 8 |
| 2026-10-30 | $0.12 | $1,227,430,270 | 3 / 8 |
| 2026-10-31 | $0.12 | $1,227,430,270 | 3 / 8 |
| 2026-11-01 | $0.12 | $1,227,430,270 | 3 / 8 |
| 2026-11-02 | $0.12 | $1,202,622,748 | 3 / 8 |
| 2026-11-03 | $0.12 | $1,213,372,748 | 3 / 9 |
| 2026-11-04 | $0.10 | $1,225,331,081 | 3 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.